Comparative Pharmacology
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER versus INDERIDE LA 120 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER versus INDERIDE LA 120 50.
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER vs INDERIDE LA 120/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist with no intrinsic sympathomimetic activity or membrane stabilizing activity. Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors predominantly in cardiac tissue.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min IV for 4 minutes. Titrate by 50 mcg/kg/min increments every 4 minutes as needed to maximum of 200 mcg/kg/min. For double-strength (20 mg/mL) formulation, adjust infusion rate accordingly.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes. Clinical context: ultra-short acting beta-blocker, steady state achieved within 30 minutes.
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
Rapid metabolism by red blood cell esterases; metabolites are inactive. Less than 2% excreted unchanged in urine.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Category A/B
Category C
Beta-Blocker
Beta-Blocker/Diuretic Combination